Function Health and NYU Grossman School of Medicine are partnering to develop AI models that identify disease markers in asymptomatic individuals by combining Function's longitudinal health data from well populations with NYU's clinical disease progression data. This approach targets cancer, cognitive decline, and cardiometabolic risk—conditions that typically develop silently for years before diagnosis.
Key Points
- Partnership pairs healthy population data with clinical disease data to detect early pathology
- Focus on three high-impact conditions: cancer, cognitive decline, cardiometabolic risk
- AI models trained to identify subtle patterns years before traditional diagnosis
Longevity Analysis
The ability to detect disease in its subclinical phase fundamentally changes the intervention timeline. Rather than responding after symptoms emerge, this model enables practitioners to identify metabolic, structural, or biochemical drift while the body's regenerative and adaptive capacity remains intact. This shifts medicine from reactive treatment to predictive management, provided the predictive models validate in independent cohorts. The clinical utility depends entirely on whether detected signals actually precede disease progression and whether early intervention on those signals produces better outcomes than standard care—questions that require rigorous prospective validation before routine implementation.
Original published by Longevity.Technology, by Kyle Umipig.